Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sucrose. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.71 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.71 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sucrose SCHEMBL1272574 | 1.00 | CDK1 (0.71) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL10405566 | 0.99 | CDK1 (0.73) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL367818 | 0.99 | CDK1 (0.73) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL2065050 | 0.97 | CDK1 (0.71) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL5972243 | 0.97 | CDK1 (0.71) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL15652705 | 0.97 | CDK1 (0.71) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL9704445 | 0.97 | CDK1 (0.71) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL6376479 | 0.97 | CDK1 (0.71) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL9747719 | 0.97 | CDK1 (0.71) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL15656196 | 0.97 | CDK1 (0.71) | CDK1CCNB1CA2CA9LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 401 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3041476-B2 | CORTICOSTEROID CONTAINING ORALLY DISINTEGRATING TABLET COMPOSITIONS FOR EOSINOPHILIC ESOPHAGITIS | ELLODI PHARMACEUTICALS L P (US) | 2023-01-25 | — | — | EP | claimed |
| CN-114086385-B | Modified fiber, bio-based degradable material and preparation method thereof | 旗众科技有限公司 | 2022-06-10 | — | — | CN | claimed |
| CN-114230994-A | Degradable environment-friendly material and preparation method thereof | 旗众科技有限公司 | 2022-03-25 | — | — | CN | claimed |
| CN-114086385-A | Modified fiber, bio-based degradable material and preparation method thereof | 旗众科技有限公司 | 2022-02-25 | — | — | CN | claimed |
| CN-105722513-B | Orally disintegrating tablet composition comprising corticosteroid for eosinophilic esophagitis | 阿代尔制药股份有限公司 | 2021-10-22 | — | — | CN | claimed |
| CN-109316490-B | Pharmaceutical composition with weight-losing effect, preparation and application of pharmaceutical composition | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | 2020-10-13 | — | — | CN | claimed |
| CN-110755541-A | A micro-enema for preventing and treating cough, asthma and common cold in children, and its preparation method | 赵逸 | 2020-02-07 | — | — | CN | claimed |
| US-10471071-B2 | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis | ADARE PHARMACEUTICALS, INC. (US) | 2019-11-12 | — | — | US | claimed |
| EP-3041476-B1 | CORTICOSTEROID CONTAINING ORALLY DISINTEGRATING TABLET COMPOSITIONS FOR EOSINOPHILIC ESOPHAGITIS | ADARE DEV I L P (US) | 2019-11-06 | — | — | EP | claimed |
| EP-3403654-B1 | ORALLY ADMINISTERED CORTICOSTEROID COMPOSITIONS | ADARE DEV I L P (US) | 2019-07-31 | — | — | EP | claimed |
| CN-102665722-A | Orally administered corticosteroid compositions | EURAND INC | 2012-09-12 | — | — | CN | claimed |
| EP-2482822-A1 | ORALLY ADMINISTERED CORTICOSTEROID COMPOSITIONS | Aptalis Pharmatech, Inc. (US) | 2012-08-08 | — | — | EP | claimed |
| WO-2011109469-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF SKIN DISEASES AND DISORDERS USING ANTIMICROBIAL PEPTIDE SEQUESTERING COMPOUNDS | NEOCUTIS SA (CH) | 2011-09-09 | — | — | WO | claimed |
| US-20110217249-A1 | Compositions and Methods for the Treatment of Skin Diseases and Disorders Using Antimicrobial Peptide Sequestering Compounds | ANTEIS SA (CH) | 2011-09-08 | — | — | US | claimed |
| US-20110081411-A1 | Orally Administered Corticosteroid Compositions | ELLODI PHARMACEUTICALS, L.P. | 2011-04-07 | — | — | US | claimed |
| WO-2011041509-A1 | ORALLY ADMINISTERED CORTICOSTEROID COMPOSITIONS | EURAND, INC. (US) | 2011-04-07 | — | — | WO | claimed |
| CN-1021629-C | Stable basic sucralfate aluminum sulfate suspension pharmaceutical composition without suspending agent | LISAPHARMA SPA (IT) | 1993-07-21 | — | — | CN | claimed |
| EP-0493380-A4 | METHOD AND COMPOSITIONS FOR NONINVASIVE DOSE-TO-EFFECT ADMINISTRATION OF LIPOPHILIC DRUGS | — | 1992-10-07 | — | — | EP | claimed |
| EP-0493380-A1 | METHOD AND COMPOSITIONS FOR NONINVASIVE DOSE-TO-EFFECT ADMINISTRATION OF LIPOPHILIC DRUGS. | UNIV UTAH RESEARCH INST (US) | 1992-07-08 | — | — | EP | claimed |
| WO-1991003233-A1 | METHOD AND COMPOSITIONS FOR NONINVASIVE DOSE-TO-EFFECT ADMINISTRATION OF LIPOPHILIC DRUGS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1991-03-21 | — | — | WO | claimed |